InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904

Stock Information for InflaRx N.V.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About InflaRx N.V.

InflaRx to Host Virtual R&D Event on June 5, 2024 and Report First Quarter 2024 Results on May 8, 2024
InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event
InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans
InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024
InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients
InflaRx Reports Third Quarter 2023 Financial Results and Provides Business Update
InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904
InflaRx's Marketing Authorization Application (MAA) for Vilobelimab for Treatment of Critically Ill COVID-19 Patients under Review by European Medicines Agency (EMA)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.